BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Role of the CCN protein family in cancer

  • Kim, Hyungjoo (Department of Life Science, Hanyang University) ;
  • Son, Seogho (Department of Life Science, Hanyang University) ;
  • Shin, Incheol (Department of Life Science, Hanyang University)
  • Received : 2018.07.20
  • Published : 2018.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

The CCN protein family is composed of six matricellular proteins, which serve regulatory roles rather than structural roles in the extracellular matrix. First identified as secreted proteins which are induced by oncogenes, the acronym CCN came from the names of the first three members: CYR61, CTGF, and NOV. All six members of the CCN family consist of four cysteine-rich modular domains. CCN proteins are known to regulate cell adhesion, proliferation, differentiation, and apoptosis. In addition, CCN proteins are associated with cardiovascular and skeletal development, injury repair, inflammation, and cancer. They function either through binding to integrin receptors or by regulating the expression and activity of growth factors and cytokines. Given their diverse roles related to the pathology of certain diseases such as fibrosis, arthritis, atherosclerosis, diabetic nephropathy, retinopathy, and cancer, there are many emerging studies targeting CCN protein signaling pathways in attempts to elucidate their potentials as therapeutic targets.

Keywords

References

  1. Aszodi A, Legate KR, Nakchbandi I and Fassler R (2006) What mouse mutants teach us about extracellular matrix function. Annu Rev Cell Dev Biol 22, 591-621 https://doi.org/10.1146/annurev.cellbio.22.010305.104258
  2. Bornstein P and Sage EH (2002) Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 14, 608-616 https://doi.org/10.1016/S0955-0674(02)00361-7
  3. Jun JI and Lau LF (2011) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10, 945-963 https://doi.org/10.1038/nrd3599
  4. Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M., Crochet J and Perbal B (1992) Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol Cell Biol 12, 10-21 https://doi.org/10.1128/MCB.12.1.10
  5. O'Brien TP, Yang GP, Sanders L and Lau LF (1990) Expression of cyr61, a growth factor-inducible immediateearly gene. Mol Cell Biol 10, 3569-3577 https://doi.org/10.1128/MCB.10.7.3569
  6. Bradham DM, Igarashi A, Potter RL and Grotendorst GR (1991) Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 114, 1285-1294 https://doi.org/10.1083/jcb.114.6.1285
  7. Holbourn KP, Acharya KR and Perbal B (2008) The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33, 461-473 https://doi.org/10.1016/j.tibs.2008.07.006
  8. Leask A and Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119, 4803-4810 https://doi.org/10.1242/jcs.03270
  9. Perbal BV and Takigawa M (2005) CCN proteins : a new family of cell growth and differentiation regulators. Imperial College Press, London ; Hackensack, NJ
  10. Fukunaga-Kalabis M, Martinez G, Liu ZJ et al (2006) CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol 175, 563-569 https://doi.org/10.1083/jcb.200602132
  11. Chen CC, Chen N and Lau LF (2001) The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem 276, 10443-10452 https://doi.org/10.1074/jbc.M008087200
  12. Grzeszkiewicz TM, Kirschling DJ, Chen N and Lau LF (2001) CYR61 stimulates human skin fibroblast migration through Integrin alpha vbeta 5 and enhances mitogenesis through integrin alpha vbeta 3, independent of its carboxyl-terminal domain. J Biol Chem 276, 21943-21950 https://doi.org/10.1074/jbc.M100978200
  13. Gao R and Brigstock DR (2006) A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2/CTGF) promotes adhesion and migration of activated pancreatic stellate cells. Gut 55, 856-862 https://doi.org/10.1136/gut.2005.079178
  14. Babic AM, Chen CC and Lau LF (1999) Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 19, 2958-2966 https://doi.org/10.1128/MCB.19.4.2958
  15. Soon LL, Yie TA, Shvarts A, Levine AJ, Su F and Tchou-Wong KM (2003) Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem 278, 11465-11470 https://doi.org/10.1074/jbc.M210945200
  16. Lake AC, Bialik A, Walsh K and Castellot JJ Jr (2003) CCN5 is a growth arrest-specific gene that regulates smooth muscle cell proliferation and motility. Am J Pathol 162, 219-231 https://doi.org/10.1016/S0002-9440(10)63813-8
  17. Lau LF and Lam SC (1999) The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 248, 44-57 https://doi.org/10.1006/excr.1999.4456
  18. Perbal B (2001) NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 54, 57-79 https://doi.org/10.1136/mp.54.2.57
  19. Fan WH, Pech M and Karnovsky MJ (2000) Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro. Eur J Cell Biol 79, 915-923 https://doi.org/10.1078/0171-9335-00122
  20. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC and Lau LF (2002) The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans. Endocrinology 143, 1441-1450 https://doi.org/10.1210/endo.143.4.8731
  21. Shimoyama T, Hiraoka S, Takemoto M et al (2010) CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration. Arterioscler Thromb Vasc Biol 30, 675-682 https://doi.org/10.1161/ATVBAHA.110.203356
  22. Yosimichi G, Nakanishi T, Nishida T, Hattori T, Takano-Yamamoto T and Takigawa M (2001) CTGF/Hcs24 induces chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK). Eur J Biochem 268, 6058-6065 https://doi.org/10.1046/j.0014-2956.2001.02553.x
  23. Zuo GW, Kohls CD, He BC et al (2010) The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol 25, 795-806
  24. Parisi MS, Gazzerro E, Rydziel S and Canalis E (2006) Expression and regulation of CCN genes in murine osteoblasts. Bone 38, 671-677 https://doi.org/10.1016/j.bone.2005.10.005
  25. Maeda A, Nishida T, Aoyama E et al (2009) CCN family 2/connective tissue growth factor modulates BMP signalling as a signal conductor, which action regulates the proliferation and differentiation of chondrocytes. J Biochem 145, 207-216
  26. Ono M, Inkson CA, Kilts TM and Young MF (2011) WISP-1/CCN4 regulates osteogenesis by enhancing BMP-2 activity. J Bone Miner Res 26, 193-208 https://doi.org/10.1002/jbmr.205
  27. Kubota S and Takigawa M (2007) CCN family proteins and angiogenesis: from embryo to adulthood. Angiogenesis 10, 1-11 https://doi.org/10.1007/s10456-006-9058-5
  28. Babic AM, Kireeva ML, Kolesnikova TV and Lau LF (1998) CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 95, 6355-6360 https://doi.org/10.1073/pnas.95.11.6355
  29. Lin CG, Leu SJ, Chen N et al (2003) CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem 278, 24200-24208 https://doi.org/10.1074/jbc.M302028200
  30. Shimo T, Nakanishi T, Nishida T et al (1999) Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 126, 137-145 https://doi.org/10.1093/oxfordjournals.jbchem.a022414
  31. Fataccioli V, Abergel V, Wingertsmann L et al (2002) Stimulation of angiogenesis by Cyr61 gene: a new therapeutic candidate. Hum Gene Ther 13, 1461-1470 https://doi.org/10.1089/10430340260185094
  32. Inoki I, Shiomi T, Hashimoto G et al (2002) Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 16, 219-221 https://doi.org/10.1096/fj.01-0332fje
  33. Nathans D, Lau LF, Christy B, Hartzell S, Nakabeppu Y and Ryder K (1988) Genomic response to growth factors. Cold Spring Harb Symp Quant Biol 53 Pt 2, 893-900 https://doi.org/10.1101/SQB.1988.053.01.102
  34. Grotendorst GR (1997) Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 8, 171-179 https://doi.org/10.1016/S1359-6101(97)00010-5
  35. Lin CG, Chen CC, Leu SJ, Grzeszkiewicz TM and Lau LF (2005) Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J Biol Chem 280, 8229-8237 https://doi.org/10.1074/jbc.M404903200
  36. Dhar A and Ray A (2010) The CCN family proteins in carcinogenesis. Exp Oncol 32, 2-9
  37. Perbal B (2001) The CCN family of genes: a brief history. Mol Pathol 54, 103-104 https://doi.org/10.1136/mp.54.2.103
  38. Bleau AM, Planque N and Perbal B (2005) CCN proteins and cancer: two to tango. Front Biosci 10, 998-1009 https://doi.org/10.2741/1594
  39. Perbal B (2006) NOV story: the way to CCN3. Cell Commun Signal 4, 3 https://doi.org/10.1186/1478-811X-4-3
  40. Gery S, Xie D, Yin D et al (2005) Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 11, 7243-7254 https://doi.org/10.1158/1078-0432.CCR-05-0231
  41. Lv H, Fan E, Sun S et al(2009) Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status. J Cell Biochem 106, 738-744 https://doi.org/10.1002/jcb.22075
  42. Watari H, Xiong Y, Hassan MK and Sakuragi N (2009) Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol 112, 229-234 https://doi.org/10.1016/j.ygyno.2008.09.039
  43. Planque N and Perbal B (2003) A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 3, 15 https://doi.org/10.1186/1475-2867-3-15
  44. Schmitz P, Gerber U, Jungel E, Schutze N, Blaheta R and Bendas G (2013) Cyr61/CCN1 affects the integrin-mediated migration of prostate cancer cells (PC-3) in vitro. Int J Clin Pharmacol Ther 51, 47-50 https://doi.org/10.5414/CPP51047
  45. Tsai MS, Hornby AE, Lakins J and Lupu R (2000) Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 60, 5603-5607
  46. Xie D, Yin D, Tong X et al (2004) Cyr61 is overexpressed in gliomas and involved in integrin-linked kinasemediated Akt and beta-catenin- TCF/Lef signaling pathways. Cancer Res 64, 1987-1996 https://doi.org/10.1158/0008-5472.CAN-03-0666
  47. Chen PP, Li WJ, Wang Y et al (2007) Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2, e534 https://doi.org/10.1371/journal.pone.0000534
  48. Maeta N, Osaki M, Shomori K et al (2007) CYR61 downregulation correlates with tumor progression by promoting MMP-7 expression in human gastric carcinoma. Oncology 73, 118-126 https://doi.org/10.1159/000121000
  49. Chien W, Kumagai T, Miller CW et al (2004) Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem 279, 53087-53096 https://doi.org/10.1074/jbc.M410254200
  50. Croci S, Landuzzi L, Nicoletti G et al (2007) Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. Pathol Oncol Res 13, 336-339 https://doi.org/10.1007/BF02940313
  51. Deng YZ, Chen PP, Wang Y et al(2007) Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem 282, 36571-36581 https://doi.org/10.1074/jbc.M704141200
  52. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K and Mansel RE (2004) Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 11, 781-791 https://doi.org/10.1677/erc.1.00825
  53. Bennewith KL, Huang X, Ham CM et al (2009) The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res 69, 775-784 https://doi.org/10.1158/0008-5472.CAN-08-0987
  54. Shakunaga T, Ozaki T, Ohara N et al (2000) Expression of connective tissue growth factor in cartilaginous tumors. Cancer 89, 1466-1473 https://doi.org/10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G
  55. Chien W, O'Kelly J, Lu D et al (2011) Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis. Int J Oncol 38, 1741-1747
  56. Kang Y, Siegel PM, Shu W et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 https://doi.org/10.1016/S1535-6108(03)00132-6
  57. Shimo T, Kubota S, Yoshioka N et al (2006) Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 21, 1045-1059 https://doi.org/10.1359/jbmr.060416
  58. Bleau AM, Planque N, Lazar N et al (2007) Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation. J Cell Biochem 101, 1475-1491 https://doi.org/10.1002/jcb.21262
  59. Gupta N, Wang H, McLeod TL et al (2001) Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol Pathol 54, 293-299 https://doi.org/10.1136/mp.54.5.293
  60. Gellhaus A, Dong X, Propson S et al (2004) Connexin43 interacts with NOV: a possible mechanism for negative regulation of cell growth in choriocarcinoma cells. J Biol Chem 279, 36931-36942 https://doi.org/10.1074/jbc.M404073200
  61. Benini S, Perbal B, Zambelli D et al (2005) In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 24, 4349-4361 https://doi.org/10.1038/sj.onc.1208620
  62. Fukunaga-Kalabis M, Martinez G, Telson SM et al (2008) Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 27, 2552-2560 https://doi.org/10.1038/sj.onc.1210896
  63. Maillard M, Cadot B, Ball RY et al (2001) Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol 54, 275-280 https://doi.org/10.1136/mp.54.4.275
  64. Manara MC, Perbal B, Benini S et al (2002) The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol 160, 849-859 https://doi.org/10.1016/S0002-9440(10)64908-5
  65. Glukhova L, Angevin E, Lavialle C et al (2001) Patterns of specific genomic alterations associated with poor prognosis in high-grade renal cell carcinomas. Cancer Genet Cytogenet 130, 105-110 https://doi.org/10.1016/S0165-4608(01)00477-0
  66. Zhang T, Zhao C, Luo L et al (2013) The clinical and prognostic significance of CCN3 expression in patients with cervical cancer. Adv Clin Exp Med 22, 839-845
  67. Pennica D, Swanson TA, Welsh JW et al (1998) WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 95, 14717-14722 https://doi.org/10.1073/pnas.95.25.14717
  68. Davies SR, Davies ML, Sanders A, Parr C, Torkington J and Jiang WG (2010) Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implications. Int J Oncol 36, 1129-1136
  69. Xie D, Nakachi K, Wang H, Elashoff R and Koeffler HP (2001) Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61, 8917-8923
  70. Chuang JY, Chang AC, Chiang IP, Tsai MH and Tang CH (2013) Apoptosis signal-regulating kinase 1 is involved in WISP-1-promoted cell motility in human oral squamous cell carcinoma cells. PLoS One 8, e78022 https://doi.org/10.1371/journal.pone.0078022
  71. Hashimoto Y, Shindo-Okada N, Tani M, Takeuchi K, Toma H and Yokota J (1996) Identification of genes differentially expressed in association with metastatic potential of K-1735 murine melanoma by messenger RNA differential display. Cancer Res 56, 5266-5271
  72. Hashimoto Y, Shindo-Okada N, Tani M et al (1998) Expression of the Elm1 gene, a novel gene of the CCN (connective tissue growth factor, Cyr61/Cef10, and neuroblastoma overexpressed gene) family, suppresses In vivo tumor growth and metastasis of K-1735 murine melanoma cells. J Exp Med 187, 289-296 https://doi.org/10.1084/jem.187.3.289
  73. Davies SR, Watkins G, Mansel RE and Jiang WG (2007) Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol 14, 1909-1918 https://doi.org/10.1245/s10434-007-9376-x
  74. Yu C, Le AT, Yeger H, Perbal B and Alman BA (2003) NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia. J Pathol 201, 609-615 https://doi.org/10.1002/path.1468
  75. Mason HR, Lake AC, Wubben JE, Nowak RA and Castellot JJ Jr (2004) The growth arrest-specific gene CCN5 is deficient in human leiomyomas and inhibits the proliferation and motility of cultured human uterine smooth muscle cells. Mol Hum Reprod 10, 181-187 https://doi.org/10.1093/molehr/gah028
  76. Dhar G, Mehta S, Banerjee S et al (2007) Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymal-transition. Cancer Lett 254, 63-70 https://doi.org/10.1016/j.canlet.2007.02.012
  77. Kouzu Y, Uzawa K, Kato M et al (2006) WISP-2 expression in human salivary gland tumors. Int J Mol Med 17, 567-573
  78. Yang Z, Yang Z, Zou Q et al (2014) A comparative study of clinicopathological significance, FGFBP1, and WISP-2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of the gallbladder. Int J Clin Oncol 19, 325-335 https://doi.org/10.1007/s10147-013-0550-9
  79. Tomimaru Y, Koga H, Yano H, de la Monte S, Wands JR and Kim M (2013) Upregulation of T-cell factor-4 isoformresponsive target genes in hepatocellular carcinoma. Liver Int 33, 1100-1112 https://doi.org/10.1111/liv.12188
  80. Colli LM, Saggioro F, Serafini LN et al(2013) Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumors. PLoS One 8, e62424 https://doi.org/10.1371/journal.pone.0062424
  81. Fritah A, Saucier C, De Wever O et al (2008) Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 28, 1114-1123 https://doi.org/10.1128/MCB.01335-07
  82. Banerjee S, Dhar G, Haque I et al (2008) CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res 68, 7606-7612\ https://doi.org/10.1158/0008-5472.CAN-08-1461
  83. Kleer CG, Zhang Y, Pan Q et al (2002) WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21, 3172-3180 https://doi.org/10.1038/sj.onc.1205462
  84. Lorenzatti G, Huang W, Pal A, Cabanillas AM and Kleer CG (2011) CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer. J Cell Sci 124, 1752-1758 https://doi.org/10.1242/jcs.084194
  85. Huang W, Zhang Y, Varambally S et al (2008) Inhibition of CCN6 (Wnt-1-induced signaling protein 3) downregulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol 172, 893-904 https://doi.org/10.2353/ajpath.2008.070899
  86. Thorstensen L, Diep CB, Meling GI et al (2001) WNT1 inducible signaling pathway protein 3, WISP-3, a novel target gene in colorectal carcinomas with microsatellite instability. Gastroenterology 121, 1275-1280 https://doi.org/10.1053/gast.2001.29570
  87. Chen CC and Lau LF (2009) Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 41, 771-783 https://doi.org/10.1016/j.biocel.2008.07.025
  88. Lau LF (2011) CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci 68, 3149-3163 https://doi.org/10.1007/s00018-011-0778-3
  89. Abreu JG, Ketpura NI, Reversade B and De Robertis EM (2002) Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 4, 599-604 https://doi.org/10.1038/ncb826
  90. Nishida T, Kubota S, Aoyama E, Janune D, Maeda A and Takigawa M (2011) Effect of CCN2 on FGF2-induced proliferation and MMP9 and MMP13 productions by chondrocytes. Endocrinology 152, 4232-4241 https://doi.org/10.1210/en.2011-0234
  91. Li J, Ye L, Owen S, Weeks HP, Zhang Z and Jiang WG (2015) Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (Review). Int J Mol Med 36, 1451-1463 https://doi.org/10.3892/ijmm.2015.2390